Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 29, 2016
Pharmacy Choice - News - Generic Drugs - July 29, 2016

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 66     Next >>     Go To Page:

7/28/16 - Animal Generic Drug User Fee Rates and Payment Procedures for Fiscal Year 2017
The Federal Food, Drug, and Cosmetic Act, as amended by the Animal Generic Drug User Fee Amendments of 2013, authorizes FDA to collect user fees for certain abbreviated applications for generic new animal drugs, for certain generic new animal drug products, and for certain sponsors of such abbreviated applications for generic new animal drugs and/o
7/28/16 - AstraZeneca says 2Q earnings fell 22 per cent
LONDON Anglo-Swedish drugmaker AstraZeneca says second-quarter earnings fell 22 per cent after sales of its blockbuster cholesterol drug Crestor dropped sharply after a generic alternative came on the market in the United States.
7/28/16 - AstraZeneca says 2Q earnings fell 22 percent
Anglo-Swedish drugmaker AstraZeneca says second-quarter earnings fell 22 percent after sales of its blockbuster cholesterol drug Crestor dropped sharply after a generic alternative came on the market in the United States. Core operating profit, which excludes one-time items such as restructuring costs and impairments, dropped to $1.41 billion fr
7/28/16 - Biosimilar User Fee Rates for Fiscal Year 2017
The Federal Food, Drug, and Cosmetic Act, as amended by the Biosimilar User Fee Act of 2012, authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development, certain applications and supplements for approval of biosimilar biological products, establishments where approved biosimilar
7/28/16 - FDA Announces Animal Generic Drug User Fee Rates, Payment Procedures for Fiscal 2017
WASHINGTON, July 28 The Department of Health and Human Services published the following notice in the Federal Register from the Food and Drug Administration:. The Federal Food, Drug, and Cosmetic Act, as amended by the Animal Generic Drug User Fee Amendments of 2013, authorizes FDA to collect user fees for certain abbreviated applications for gen
7/28/16 - FDA Announces Biosimilar User Fee Rates for Fiscal 2017
WASHINGTON, July 28 The Department of Health and Human Services published the following notice in the Federal Register from the Food and Drug Administration:. Dates: No later than 5 calendar days after FDA grants the sponsor's request for a BPD meeting for that product, or upon the date of submission of an IND describing an investigation that FDA
7/28/16 - Fosun Pharma To Acquire Approx. 86% Stake In Gland; KKR To Divest Its Full Stake
WASHINGTON- Gland Pharma Limited, an Indian pure-play generic injectable pharmaceutical products company, announced a definitive agreement under which Shanghai Fosun Pharmaceutical Co. Ltd., a Chinese health care provider, will acquire an approximate 86% stake in Gland for up to $1.26 billion. Fosun Pharma will purchase all shares of Gland owned by
7/28/16 - Frontage Laboratories, Inc. Announces Formation of FJ Pharma, LLC, a Joint Venture with Zhejiang Jiuzhou Pharmaceutical Co, Ltd. to Provide API Development and Manufacturing Services [Palestine Chronicle, The]
Frontage Laboratories, Inc. announced that it has established a joint venture with Zhejiang Jiuzhou Pharmaceutical Co., Ltd. to provide enhanced access to high quality and economical API& intermediate development and manufacturing services to new US clients focused on New Chemical Entities and vertically-integrated generic APIs that are developed..
7/28/16 - Gland Pharma to be Acquired by Fosun Pharma
Gland Pharma Limited, a leading Indian pure-play generic injectable pharmaceutical products company, today announced the signing of a definitive agreement under which Shanghai Fosun Pharmaceutical Co. Ltd., a leading Chinese health care provider, will acquire an approximate 86% stake in Gland for up to US $1.26 billion. Ravi Penmetsa, will continue
7/28/16 - Glenmark ends in green; gets FDA nod for Potassium Chloride ER tablets [India Infoline News Service]
Glenmark Pharma ended 0.3% higher at Rs.853.05 on BSE after the company s parent company received FDA nod for new drug. Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food& Drug Administration for Potassium Chloride Extended-Release Tablets USP, 10 mEq and 20 mEq, the generic version of K-Dur Extended-Rel
7/28/16 - Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen [Khaleej Times (United Arab Emirates)]
-Hemispherx Biopharma announced today that it has reached an agreement with Avrio Biopharmaceuticals, Irvine California, to serve as an additional contract manufacturer of Hemispherxs experimental drug, Ampligen, also known by its generic name rintatolimod. Avrio, an FDA inspected facility, has the capabilities for the compounding and fill/finish o
7/28/16 - JAZZ PHARMACEUTICALS PLC FILES (8-K) Disclosing Other Events
In November 2010, Jazz Pharmaceuticals, Inc., a wholly owned subsidiary of the Company, filed a lawsuit in the United States District Court for the District of New Jersey against Roxane Laboratories, Inc. seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem that would infringe the Company's patents.
7/28/16 - Korea Kolmar to supply generic CNS treatment to Abbott [Tripoli Post, The (Libya)]
Korea Kolmar has signed an agreement with Abbott Korea for the exclusive supply of drugs, it announced on July 27. The domestic market for pregabalin, known to be effective for reducing central neuropathic pain, is estimated to be 43 billion won. And when Pfizers patent for the use of pregabalin in the neuropathic pain in adults, branded under Lyri
7/28/16 - Korean biosimilar drugs lift European market share [Korea Times]
Biogen, a U.S. multinational biotechnology company, announced its second-quarter results last Friday, including the sales records of Benepali, an arthritis drug developed by Samsung Bioepis and marketed by it in Europe. Samsung Bioepis has been making Benepali, its first biosimilar product, in Biogen's factory in Denmark. Sales of Inflectra, a rheu
7/28/16 - Mylan to divest two generic drugs to win antitrust clearance for Meda acquisition [The Pittsburgh Tribune-Review]
July 28 Mylan NV is divesting two generic drugs to resolve concerns from U.S. regulators that its acquisition of Swedish specialty drugmaker Meda AB would have led to higher prices for the medicines. Mylan, which is based in the Netherlands and run from offices in Cecil, agreed to sell the rights and assets related to generic felbamate, a treatme
7/28/16 - Pharma-Docs Nexus Deprives Poor of low-cost medicine: MedKart
AHMADABAD, GUJARAT, INDIA, July 28, 2016/ EINPresswire.com/ The unholy nexus between drug makers and doctors to prevent affordable generic medicines reaching poor is a blatant violation of Medical Council of India s directives and also against the Constitution, which guarantees citizen their right to access quality, safe and affordable medicin
7/28/16 - Saneca inks Eastern Europe manufacturing and registration deal with Xantis [Daily Tribune (Bahrain)]
The marketing rights being sold to Xantis Pharma include a wide range of products covering cardiovascular, pain management, urology and sexual health indications, said Jeremy Drummond, sales and marketing director at Saneca. These are generic products that Saneca has developed and registered in East European markets, he told in-pharmatechnologist.c
7/28/16 - Teligent, Inc. Announces Second Quarter 2016 Results
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2016. Total revenues of $17.1 million in the second quarter of 2016, an increase of 93% over the same quarter in 2015. Total net revenues generated from the sale of our generic topical and injec
7/28/16 - Teva Agrees to Divest 79 Pharma Products to Settle Actavis Generics Merger Issues [Daily Star, The (Lebanon)]
Teva Pharmaceutical Industries Ltd. has agreed to sell the rights and assets related to 79 pharmaceutical products to settle FTC charges that its proposed $40.5 billion acquisition of Allergan plcs generic pharmaceutical business would be anticompetitive. The FTC order will preserve competition in U.S. pharmaceutical markets where Teva and Allergan
7/28/16 - Teva agrees to largest-ever drug divestiture in FTC pharma merger case [tayyar.org (Lebanon)]
The divestiture is the largest ever in an FTC pharmaceutical merger case, according to the FTC. A spokeswoman for Israel- based Teva declined to comment on the divestiture Wednesday, but the drugmaker did issue a release Wednesday announcing that its agreement with the FTC will allow it to acquire Allergan`s generics business, known as Actavis Gene
7/28/16 - Teva Gets Clearance From The U.S. FTC For Actavis Generics Acquisition
PETAH TIKVA- Teva Pharmaceutical Industries Ltd., and Allergan plc announced that the U.S. Federal Trade Commission or FTC has accepted the proposed consent order in connection with the pending acquisition of Allergan's generics business by Teva Pharmaceutical Industries Ltd.. Once the transaction is completed, Teva will have approximately 338 prod
7/28/16 - Teva Receives Clearance from the U.S. Federal Trade Commission for Actavis Generics Acquisition [Palestine Chronicle, The]
Teva Pharmaceutical Industries Ltd., and Allergan plc today announced that the U.S. Federal Trade Commission has accepted the proposed consent order in connection with the pending acquisition of Allergans generics business by Teva Pharmaceutical Industries Ltd.. Mr. Vigodman continued, The new Teva will be ideally positioned to realize the...
7/28/16 - Teva receives US clearance for Actavis acquisition [Globes, Tel Aviv, Israel]
July 28 Teva Pharmaceutical Industries Ltd. last night announced that the US Federal Trade Commission had consented to its acquisition of Allergan's generics business. The FTC said that Teva had satisfied the regulatory approval requirements under the purchase agreement to complete the acquisition of Actavis Generics. Last week, Teva raised over
7/28/16 - Teva strengthens hold in generic drugs, merges with Allergen [Big News Network (United Arab Emirates)]
WASHINGTON, U.S.- Israeli pharmaceutical company, Teva, with the nod from the U.S. Federal Trade Commission, has inked a deal worth $40.5 billion to acquire the generic business of Allergen. The divestment of drugs like anesthetics, antibiotics, weight-loss drugs and oral contraceptives will benefit over 11 companies which include Mayne Pharma Grou
7/28/16 - Teva's $$40.5 Billion deal expected to go through next week [Arutz Sheva (Israel)]
Israeli pharmaceutical company wins regulatory approval for acquisition of Allergan, conditional upon giving up some of its products. The Federal Trade Commision, has approved Israeli-based pharmaceutical company Teva's acquisition of Allergan's generic drug production business, after a yearlong bid to win the approval of the regulatory body, the W
Articles(s): 1 - 25 of 66     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415